Arax Advisory Partners’s Definium Therapeutics DFTX Stock Holding History

Arax Advisory Partners’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.81K	Sell	466 -13	-3%	-$221	﹤0.01%	2511
2025 Q4	$6.41K	Buy	+479	New	+$5.93K	﹤0.01%	2713
2025 Q3	–	Sell	-501	Closed	-$3.25K	–	4050
2025 Q2	$3.25K	Buy	501 +237	+90%	+$1.56K	﹤0.01%	2391
2025 Q1	$1.54K	Sell	264 -12	-4%	-$86	﹤0.01%	2158
2024 Q4	$1.92K	Buy	276 +248	+886%	+$1.71K	﹤0.01%	2021
2024 Q3	$160	Hold	28	–	–	﹤0.01%	2530
2024 Q2	$202	Hold	28	–	–	﹤0.01%	2438
2024 Q1	$264	Hold	28	–	–	﹤0.01%	1267
2023 Q4	$103	Hold	28	–	–	﹤0.01%	1310
2023 Q3	$88	Hold	28	–	–	﹤0.01%	1300
2023 Q2	$100	Hold	28	–	–	﹤0.01%	1250
2023 Q1	$89	Hold	28	–	–	﹤0.01%	1252
2022 Q4	$62	Buy	+28	New	+$78	﹤0.01%	1257
2022 Q1	–	Sell	-29	Closed	-$1K	–	1186
2021 Q4	$1K	Buy	29 +3	+12%	+$96	﹤0.01%	1041
2021 Q3	$1K	Hold	26	–	–	﹤0.01%	921
2021 Q2	$1K	Buy	+26	New	+$1.36K	﹤0.01%	886

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arax Advisory Partners's DFTX Position: Q1 2026 in Review

Arax Advisory Partners reduced its Definium Therapeutics (DFTX) stake by 2.7% in Q1 2026, selling an estimated $221 and leaving 466 shares worth $8.81K. The position accounts for ﹤0.01% of the portfolio, ranked #2511.

Arax Advisory Partners first reported a position in DFTX in Q2 2021 and has held it in 16 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

Arax Advisory Partners held 466 shares of Definium Therapeutics worth $8.81K as of Q1 2026.
Arax Advisory Partners sold 13 Definium Therapeutics shares in Q1 2026, an estimated $221.
Definium Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #2511 holding.
Arax Advisory Partners first reported a position in Definium Therapeutics in Q2 2021 and has held it in 16 quarters since.
247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.